GeneDx (NASDAQ:WGS) Issues Quarterly Earnings Results, Beats Estimates By $0.66 EPS

GeneDx (NASDAQ:WGS) issued its earnings results on Tuesday. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.66, Zacks reports. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. GeneDx updated its FY 2025 guidance to EPS.

GeneDx Trading Down 2.1 %

NASDAQ:WGS opened at $76.35 on Tuesday. GeneDx has a 52 week low of $4.34 and a 52 week high of $98.87. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. The firm’s fifty day moving average is $76.48 and its 200-day moving average is $61.21. The firm has a market cap of $2.10 billion, a P/E ratio of -24.55 and a beta of 2.01.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Wells Fargo & Company boosted their price objective on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. Craig Hallum upped their price objective on GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. The Goldman Sachs Group lifted their target price on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Finally, TD Cowen raised their price target on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $70.67.

Insider Buying and Selling

In related news, CFO Kevin Feeley sold 12,019 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $73.76, for a total transaction of $886,521.44. Following the completion of the sale, the chief financial officer now owns 32,932 shares of the company’s stock, valued at $2,429,064.32. This trade represents a 26.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Katherine Stueland sold 10,501 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $76.75, for a total value of $805,951.75. Following the completion of the transaction, the chief executive officer now directly owns 71,146 shares in the company, valued at approximately $5,460,455.50. This trade represents a 12.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 139,603 shares of company stock valued at $12,223,041 over the last quarter. Insiders own 27.30% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.